SANGAMO THERAPEUTICS, INC. Update: 2025 Financial Results

If you follow Sangamo Therapeutics, you know biotech stocks can be a rollercoaster. Let’s cut through the corporate jargon and look at what is actually happening with the company.

---

1. What happened?

On March 30, 2026, Sangamo released its 2025 Annual Report. The company is officially pivoting to become a neurology-focused biotech. They are moving away from legacy projects to concentrate their capital on their proprietary "zinc finger" gene-regulation technology. Key updates include moving ST-920 for Fabry disease into late-stage testing and initiating early-stage work on ST-501, a therapy for chronic nerve pain.

2. The "Money" Situation

This is the most critical factor for your investment thesis:

• The Loss: Sangamo reported a net loss of $134.5 million for 2025, with $118.2 million of that driven by research and development expenses.
• The Bank Account: As of December 31, 2025, the company held $20.9 million in cash and investments.
• The Runway: The company’s financial position is tight. Management expects their current cash to be exhausted by the third quarter of 2026.

3. Why does this matter?

For a pre-revenue biotech company, "runway"—how long they can operate before running out of cash—is the primary risk factor.

• The Potential: Their lead project, ST-920, has shown promising results in early trials for Fabry disease. Furthermore, their history of partnerships with industry giants like Eli Lilly and Biogen serves as a "stamp of approval" for their underlying technology.
• The Risk: The company is facing a "liquidity cliff." With only $21 million in the bank, they must secure additional capital soon. To survive past mid-2026, they need a major licensing deal or they will likely need to issue more shares. Issuing more shares dilutes existing shareholders, which typically puts downward pressure on the stock price.

4. Who is affected?

• Investors: Shareholders should expect high volatility. The stock price is currently hyper-sensitive to clinical trial updates and news regarding potential partnerships. The company is in a "prove it" phase where every milestone is a make-or-break event.
• Patients: The development timeline for treatments like ST-920 is directly tied to the company’s ability to maintain funding. If cash reserves dry up, trials could be paused or cancelled, directly impacting patient access to these therapies.

5. What should you look for next?

• The Summer 2026 Deadline: Watch for the official filing of the ST-920 application with the FDA. A successful filing would be a major de-risking event for the company.
• Partnership News: Keep an eye out for announcements regarding new licensing deals. A deal bringing in $50 million to $100 million would significantly extend their runway and reduce the immediate need for dilutive share offerings.

6. A quick tip for investors

• Watch the Cash: Monitor the "Cash and Cash Equivalents" line in their quarterly filings. If the balance drops below $10 million, the company will be under extreme pressure to raise capital, which often results in a stock offering.
• The Bottom Line: Investing in Sangamo at this stage is a high-risk bet on their clinical success and their ability to navigate a tight financial window. Only invest what you are comfortable losing, and keep a close eye on their cash burn rate.

---

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and shouldn't be taken as professional investment advice. Always do your own research before buying or selling stocks!